UroGen Pharma Ltd. — Director's Dealing 2019

Jan 10, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2019-01-01

Reporting Person: Mullennix Stephen (COO)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Restricted Stock Unit	$		Ordinary Shares (12500)		Direct
Employee Stock Option (right to buy)	$55.50	2028-03-07	Ordinary Shares (45000)		Direct
Restricted Stock Unit	$		Ordinary Shares (3607)		Direct
Employee Stock Option (right to buy)	$39.10	2028-10-28	Ordinary Shares (20000)		Direct
Restricted Stock Unit	$		Ordinary Shares (5000)		Direct

Footnotes

F1: 33.33% of the restricted stock units ("RSUs") will vest on February 14, 2019 and 8.33% of the remaining RSUs will vest in equal quarterly installments thereafter.

F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F3: 33.33% of the shares underlying the stock option will vest on February 14, 2019 and 8.33% of the remaining shares will vest each in equal quarterly installments thereafter.